These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 33207545)

  • 1. Comprehensive Gene Mutation Profiling of Circulating Tumor DNA in Ovarian Cancer: Its Pathological and Prognostic Impact.
    Noguchi T; Iwahashi N; Sakai K; Matsuda K; Matsukawa H; Toujima S; Nishio K; Ino K
    Cancers (Basel); 2020 Nov; 12(11):. PubMed ID: 33207545
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liquid biopsy-based comprehensive gene mutation profiling for gynecological cancer using CAncer Personalized Profiling by deep Sequencing.
    Iwahashi N; Sakai K; Noguchi T; Yahata T; Matsukawa H; Toujima S; Nishio K; Ino K
    Sci Rep; 2019 Jul; 9(1):10426. PubMed ID: 31320709
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Landscape of Actionable Genomic Alterations by Next-Generation Sequencing in Tumor Tissue Versus Circulating Tumor DNA in Chinese Patients With Non-Small Cell Lung Cancer.
    Cai J; Jiang H; Li S; Yan X; Wang M; Li N; Zhu C; Dong H; Wang D; Xu Y; Xie H; Wu S; Lou J; Zhao J; Li Q
    Front Oncol; 2021; 11():751106. PubMed ID: 35273907
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutations in circulating tumor DNA detected in the postoperative period predict poor survival in patients with ovarian cancer.
    Chao A; Chen SJ; Chen HC; Tan KT; Hsiao W; Jung SM; Yang LY; Huang KG; Chou HH; Huang HJ; Chang TC; Chao AS; Lee YH; Wu RC; Lai CH
    Biomed J; 2023 Oct; 46(5):100563. PubMed ID: 36208860
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification and clinical significance of somatic oncogenic mutations in epithelial ovarian cancer.
    Watanabe T; Nanamiya H; Endo Y; Kojima M; Nomura S; Furukawa S; Soeda S; Tamura H; Ryufuku M; Tanaka D; Isogai T; Imai JI; Watanabe S; Fujimori K
    J Ovarian Res; 2021 Oct; 14(1):129. PubMed ID: 34615547
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comprehensive gene mutation analysis of liquid biopsy samples from patients with metastatic colorectal cancer to the ovary: A case report.
    Iwahashi N; Sakai K; Noguchi T; Yahata T; Toujima S; Nishio K; Ino K
    Oncol Lett; 2018 Nov; 16(5):6431-6436. PubMed ID: 30405780
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Analysis of the feasibility and prognostic value of circulating tumor DNA in detecting gene mutations in small cell lung cancer].
    Jin Y; Chen YM; Hu X; Tang HR; Yu XM; Fan Y; Xu YJ; Xu HM; Li PS; Li Q; Chang LP; Guan YF; Chen M
    Zhonghua Yi Xue Za Zhi; 2020 Dec; 100(45):3614-3621. PubMed ID: 33333686
    [No Abstract]   [Full Text] [Related]  

  • 8. Changes in the gene mutation profiles of circulating tumor DNA detected using CAPP-Seq in neoadjuvant chemotherapy-treated advanced ovarian cancer.
    Noguchi T; Sakai K; Iwahashi N; Matsuda K; Matsukawa H; Yahata T; Toujima S; Nishio K; Ino K
    Oncol Lett; 2020 Apr; 19(4):2713-2720. PubMed ID: 32218822
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Whole-genome/exome analysis of circulating tumor DNA and comparison to tumor genomics from patients with heavily pre-treated ovarian cancer: subset analysis of the PERMED-01 trial.
    Sabatier R; Garnier S; Guille A; Carbuccia N; Pakradouni J; Adelaide J; Provansal M; Cappiello M; Rousseau F; Chaffanet M; Birnbaum D; Mamessier E; Gonçalves A; Bertucci F
    Front Oncol; 2022; 12():946257. PubMed ID: 35965534
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hybrid Capture-Based Genomic Profiling of Circulating Tumor DNA from Patients with Advanced Non-Small Cell Lung Cancer.
    Schrock AB; Welsh A; Chung JH; Pavlick D; Bernicker EH; Creelan BC; Forcier B; Ross JS; Stephens PJ; Ali SM; Dagogo-Jack I; Shaw AT; Li T; Ou SI; Miller VA
    J Thorac Oncol; 2019 Feb; 14(2):255-264. PubMed ID: 30368012
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TP53 mutations are common in all subtypes of epithelial ovarian cancer and occur concomitantly with KRAS mutations in the mucinous type.
    Rechsteiner M; Zimmermann AK; Wild PJ; Caduff R; von Teichman A; Fink D; Moch H; Noske A
    Exp Mol Pathol; 2013 Oct; 95(2):235-41. PubMed ID: 23965232
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Longitudinal Circulating Tumor DNA Profiling in Metastatic Colorectal Cancer During Anti-EGFR Therapy.
    Yang W; Zou J; Li Y; Liu R; Yan Z; Chen S; Zhao X; Guo W; Huang M; Li W; Zhu X; Chen Z
    Front Oncol; 2022; 12():830816. PubMed ID: 35280779
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of EGFR and KRAS in circulating tumor DNA in patients with advanced non-small cell lung cancer: a systematic review and meta-analysis.
    Fan G; Zhang K; Ding J; Li J
    Oncotarget; 2017 May; 8(20):33922-33932. PubMed ID: 28430611
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prospective study of the efficacy and utility of TP53 mutations in circulating tumor DNA as a non-invasive biomarker of treatment response monitoring in patients with high-grade serous ovarian carcinoma.
    Kim YM; Lee SW; Lee YJ; Lee HY; Lee JE; Choi EK
    J Gynecol Oncol; 2019 May; 30(3):e32. PubMed ID: 30887755
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cell-free circulating tumor DNA supplementing tissue biopsies for identification of targetable mutations: Implications for precision medicine and considerations for reconciling results.
    Hicks JK; Saller J; Wang E; Boyle T; Gray JE
    Lung Cancer; 2017 Sep; 111():135-138. PubMed ID: 28838384
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The predictive and prognostic significance of liquid biopsy in advanced epidermal growth factor receptor-mutated non-small cell lung cancer: A prospective study.
    Ding PN; Becker TM; Bray VJ; Chua W; Ma YF; Lynch D; Po J; Luk AWS; Caixeiro N; de Souza P; Roberts TL
    Lung Cancer; 2019 Aug; 134():187-193. PubMed ID: 31319980
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extensive mutational ctDNA profiles reflect High-grade serous cancer tumors and reveal emerging mutations at recurrence.
    Marchi G; Rajavuori A; Nguyen MTN; Huhtinen K; Oksa S; Hietanen S; Hautaniemi S; Hynninen J; Oikkonen J
    Transl Oncol; 2024 Jan; 39():101814. PubMed ID: 37924564
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preoperative ctDNA Levels Are Associated With Poor Overall Survival in Patients With Ovarian Cancer.
    Dobilas A; Chen Y; Brueffer C; Leandersson P; Saal LH; Borgfeldt C
    Cancer Genomics Proteomics; 2023 Dec; 20(6suppl):763-770. PubMed ID: 38035709
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating tumor DNA detection is correlated to histologic types in patients with early-stage non-small-cell lung cancer.
    Zhang B; Niu X; Zhang Q; Wang C; Liu B; Yue D; Li C; Giaccone G; Li S; Gao L; Zhang H; Wang J; Yang H; Wu R; Ni P; Wang C; Ye M; Liu W
    Lung Cancer; 2019 Aug; 134():108-116. PubMed ID: 31319968
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TP53 mutation and MET amplification in circulating tumor DNA analysis predict disease progression in patients with advanced gastric cancer.
    Li J; Li Z; Ding Y; Xu Y; Zhu X; Cao N; Huang C; Qin M; Liu F; Zhao A
    PeerJ; 2021; 9():e11146. PubMed ID: 33959414
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.